Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imilecleucel-T

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

- PMLiVE

Merck KGaA loses global head of R&D

Senior reshuffle also sees departure of head of Merck Millipore

- PMLiVE

Genzyme MS campaign to raise awareness of swimming benefits

Will work with the Multiple Sclerosis Association of America

- PMLiVE

Uptake challenges for personalised medicines and companion diagnostics

Are healthcare systems ready for joint assessment?

- PMLiVE

Uptake challenges for personalised medicines and companion diagnostics

Are healthcare systems ready for joint assessment?

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

- PMLiVE

Merck KGaA appoints biosimilar head

Simon Sturge joins from Boehringer Ingelheim

- PMLiVE

Merck appoints new legal and auditing heads

Friederike Rotsch and Barbara Weiland take on senior roles

- PMLiVE

Pfizer partners with Siemens on diagnostics

Will develop companion diagnostics to support clinical studies

Biogen Idec building

EC approves Biogen’s oral MS drug Tecfidera

Will compete with Novartis' Gilenya and Sanofi's Aubagio

- PMLiVE

Merck KGaA loses CFO to Lanxess

Matthias Zachert joins chemical company as CEO

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links